CLCS (Cell Source) EPS (Diluted): $-0.13 (TTM As of Dec. 2024)

What is Cell Source EPS (Diluted)?

Cell Source CLCS -9.64% 35 EPS (Diluted) is $-0.13 as of Dec. 2024. GuruFocus rates CLCS with a GF Score™ of 35/100.

Cell Source's Earnings per Share (Diluted) for the three months ended in Dec. 2024 was $-0.01. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was $-0.13.

Cell Source's EPS (Basic) for the three months ended in Dec. 2024 was $-0.01. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2024 was $-0.13.

Cell Source's EPS without NRI for the three months ended in Dec. 2024 was $-0.02. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2024 was $-0.14.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

Cell Source (OTCPK:CLCS) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Cell Source EPS (Diluted) Related Terms

Cell Source EPS (Diluted) Historical Data

* Premium members only.

The historical data trend for Cell Source's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cell Source EPS (Diluted) Chart

Cell Source Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

EPS (Diluted)

Get a 7-Day Free Trial

-0.19

-0.18

-0.17

-0.14

Cell Source Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
EPS (Diluted)	Get a 7-Day Free Trial															-0.03	-0.04	-0.04	-0.04	-0.01

CLCS vs EDSA, CTXR, ASBP: EPS (Diluted) Comparison

For the Biotechnology subindustry, Cell Source's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cell Source PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cell Source's PE Ratio distribution charts can be found below:

* The bar in red indicates where Cell Source's PE Ratio falls into.

Save Embed

35GF Score

Cell Source Inc CLCS

EPS (Diluted) is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Cell Source EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Cell Source's Diluted EPS for the fiscal year that ended in Dec. 2024 is calculated as

Diluted EPS (A: Dec. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-4.513	-	1.375)	/	41.871
	=	-0.14

Cell Source's Diluted EPS for the quarter that ended in Dec. 2024 is calculated as

Diluted EPS (Q: Dec. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-0.331	-	0.358)	/	43.517
	=	-0.02

EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.13

Frequently Asked Questions Learn more about EPS (Diluted) →

What does a EPS (Diluted) of $-0.13 mean?

Cell Source (CLCS) has a EPS (Diluted) of $-0.13 as of Dec. 2024. Earnings per share (diluted) equals net income divided by the diluted average shares outstanding. View historical data on Cell Source and its competitors.

Is Cell Source's EPS (Diluted) too high?

Cell Source's current EPS (Diluted) is $-0.13. Overall, Cell Source has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.

How does Cell Source's EPS (Diluted) compare to EDSA and CTXR?

Cell Source's EPS (Diluted) of $-0.13 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EPS (Diluted) for a Biotechnology company?

A good EPS (Diluted) depends on the Biotechnology industry context. However, EPS (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EPS (Diluted) mean?

A high EPS (Diluted) can signal that a stock is expensive relative to its fundamentals. Earnings per share (diluted) equals net income divided by the diluted average shares outstanding. View historical data on Cell Source and its competitors. Cell Source's current EPS (Diluted) is $-0.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Cell Source stock overvalued right now?

Cell Source (CLCS) has a current EPS (Diluted) of $-0.13. The current EPS (Diluted) is $-0.13. Cell Source's overall GF Score™ is 35/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EPS (Diluted) calculated?

EPS (Diluted) is calculated from a company's financial statements. For Cell Source (CLCS), the current EPS (Diluted) is $-0.13 as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cell Source Business Description

Industry Healthcare Biotechnology

Comparable Companies EDSA CTXR ASBP CLRB ABP CASI SYBX LEXX THAR LGVN VRTX ASX:CSL REGN ALNY XKRX:207940 XBRU:ARGX XBRU:UCB ONC INSM XKRX:068270

Address 57 West 57th Street, Suite 400, New York, NY, USA, 10019

Website https://www.cell-source.com

Cell Source Inc is a biotechnology company focused on developing cell therapy treatments focused on immunotherapy. The company is involved with the development of proprietary immune system management technology. The company's subsidiary commercializes a suite of inventions relating to certain cancer treatments. The other products include Anti-rejection Veto Cell tolerance therapy for both matched and mismatched allogeneic bone marrow transplantations and Anti-rejection Veto Cell tolerance therapy for both matched as well as mismatched organ transplantation.

35GF Score

Get the complete analysis for CLCS

EPS (Diluted) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.75

Price

View CLCS Analysis

See EPS (Diluted) data for all stocks →